Clinical trials: TACE
Advanced Hepatocellular Carcinoma
Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
This is a multicentri prospective cohort study to investigate the safety and efficacy of external beam radiation (RT) combined with transarterial chemoembolization (TACE) and lenvatinib vs TACE and lenvatinib in the treatment of…
- Trial name
- NCT05592197
- Testing
- Lenvatinib, TACE, External beam radiation (RT)
- Where
- China
- Sponsor
- Sun Yat-sen University
Large HCC Patients, Stereotactic Body Radiation Therapy
Comparison of Efficacy in SBRT of Large HCC With or Without TACE
The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The…
- Conditions
- Large HCC Patients, Stereotactic Body Radiation Therapy, Transcatheter Arterial Chemoembolization
- Trial name
- NCT04512846
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing 302 Hospital
Hepatocellular Carcinoma, Surgery
TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC.
- Conditions
- Hepatocellular Carcinoma, Surgery, Ablation
- Trial name
- TACE-RFA (NCT01833286)
- Testing
- TACE+RFA, re-resection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Application of Integrated Proteomic and Serum Metabolomic Analysis in Efficacy and Prognosis Assessment: A multi-omics analysis based on gut microbiota to evaluate the predictive value of microbial-derived proteins and…
- Trial name
- NCT06540508
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- TAQE (NCT05842174)
- Testing
- Hydroxychloroquine, Lipiodol
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Advanced Hepatocellular Carcinoma (HCC)
The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) is widely applied and shows good efficacy in advanced hepatocellular carcinoma (HCC). Recently, hepatic arterial infusion chemotherapy (HAIC) has also gained popularity in the treatment of…
- Trial name
- NCT05862181
- Testing
- DEB-TACE plus HAIC or HAIC alone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
The role of transarterial chemoembolization (TACE) as the standard therapy for intermediate-stage hepatocellular carcinoma (HCC) is being challenged by increasing studies which showed that liver resection (LR) is a safe and…
- Trial name
- NCT02755311
- Testing
- liver resection, transarterial chemoembolization, carboplatin
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI)
Liver transplantation (LT) represents the best treatment for patients with selected, early stage hepatocellular carcinoma (HCC).
- Trial name
- RADBRI (NCT03172559)
- Testing
- Stereotactic body radiotherapy
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma, Transarterial Chemoembolization
Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
Previous studies have confirmed that limb pain caused by oxaliplatin chemotherapy is related to spinal cord central sensitization - induced hyperalgesia through oxaliplatin activating spinal cord NMDA receptor(N-methyl-D-aspartic…
- Conditions
- Hepatocellular Carcinoma, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy, Pain
- Trial name
- TACE-HAIC (NCT05416073)
- Testing
- Esketamine, Sufentanil
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Hepatocellular Carcinoma Non-resectable
SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC
This multicenter retrospective study evaluated the efficacy and safety of selective internal radiation therapy (SIRT) combined with lenvatinib and PD-(L)1 inhibitors (SIRT-L-P) versus transarterial chemoembolization (TACE)…
- Trial name
- NCT06916546
- Testing
- SIRT-L-P, TACE-L-P
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Cholangiocarcinoma
International Registry on Cholangiocarcinoma Treatment
Cholangiocarcinoma is a rare and very aggressive neoplasm that arises from the biliary epithelium, constitutes approximately 2% of all reported cancer, and accounts for about 3% of all gastrointestinal malignancies.
- Trial name
- CHOLANGIO (NCT01920503)
- Testing
- Doxorubicin
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
Hepatocellular Carcinoma (HCC), Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
This study is a prospective, randomized, controlled, open, phase II, multicenter clinical study, which aims to evaluate the efficacy and safety of lenvatinib for adjuvant treatment of high-risk recurrent liver cancer after…
- Trial name
- NCT06762782
- Testing
- Postoperative adjuvant lenvatinib, Supportive care measures
- Where
- China
- Volunteers
- 276 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma
HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large and unresectable hepatocellular…
- Trial name
- NCT03048123
- Testing
- Hepatic arterial infusion, Transarterial chemoembolization, Folfox Protocol
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Prospective Liver Study
This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.
- Trial name
- NCT01539993
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Emory University
Hepatocellular Carcinoma, TACE
Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1
In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced…
- Conditions
- Hepatocellular Carcinoma, TACE, Notch1, Rg3
- Trial name
- NCT02724358
- Testing
- TACE, Rg3, TACE + Rg3
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH
The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on the prognosis of patients with microvascular invasion presence(MVI) and overexpression of Aspartate-β-hydroxylase(ASPH).
- Trial name
- NCT02587884
- Testing
- TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization
The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
We adopted the prospective cohort study to compare the safety and efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody in the treatment of advanced unresectable liver…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor, Immune Checkpoint Blockade
- Trial name
- NCT04997850
- Testing
- lenvatinib + sindilimab/carrelizumab, TACE
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Xinrui Zhu，MD
Liver Cancer, Surgery
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
This observational clinical cohort study aims to evaluate the clinical utility of LiverMultiScan in quantifying liver health prior to liver resection or TACE.
- Conditions
- Liver Cancer, Surgery, Liver Regeneration, Colorectal Cancer Metastatic
- Trial name
- Hepatica (NCT03213314)
- Testing
- Multiparameter magnetic resonance imaging
- Where
- 2 sites in United Kingdom
- Volunteers
- 149 people
- Sponsor
- University of Edinburgh
Unresectable Hepatocellular Carcinoma
SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
To evaluate the efficacy and safety of yttrium-90 carbon microspheres versus cTACE in patients with unresectable hepatocellular carcinoma
- Trial name
- NCT06909708
- Testing
- SIRT, cTACE
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma
The current randomized controlled trial comparing LEM and TACE aims to evaluate the safety and efficacy of LEM as compared to TACE for treating patients with unresectable HCC.
- Trial name
- NCT00467974
- Testing
- TEA with LEM, TACE
- Where
- 3 sites in Hong Kong
- Volunteers
- 98 people
- Sponsor
- Chinese University of Hong Kong